(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.29%) $79.22
(-0.23%) $2.18
(-0.27%) $2 316.10
(-0.13%) $27.57
(0.02%) $984.80
(0.08%) $0.930
(0.06%) $10.91
(0.09%) $0.800
(0.32%) $91.74
Live Chart Being Loaded With Signals
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives...
Stats | |
---|---|
本日の出来高 | 26 924.00 |
平均出来高 | 24 499.00 |
時価総額 | 1.60B |
EPS | INR0 ( 2024-02-11 ) |
次の収益日 | ( INR0 ) 2024-05-27 |
Last Dividend | INR1.000 ( 2023-09-18 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 45.90 |
ATR14 | INR0.326 (0.32%) |
ボリューム 相関
Bal Pharma Limited 相関
10 最も正の相関 | |
---|---|
EMIL.NS | 0.925 |
INDIGOPNTS.NS | 0.921 |
MEDICAMEQ.NS | 0.921 |
GOCOLORS.NS | 0.92 |
NAVNETEDUL.NS | 0.919 |
SABEVENTS.NS | 0.916 |
ASAHISONG.NS | 0.915 |
MCLEODRUSS.NS | 0.912 |
SGL.NS | 0.91 |
IGPL.NS | 0.91 |
10 最も負の相関 | |
---|---|
RAJRILTD.NS | -0.92 |
4THDIM.NS | -0.915 |
LTGILTBEES.NS | -0.898 |
ISMTLTD.NS | -0.889 |
GNA.NS | -0.865 |
KAYNES.NS | -0.865 |
JINDCOT.NS | -0.858 |
KIRLFER.NS | -0.852 |
SYMPHONY.NS | -0.85 |
SHRIRAMEPC.NS | -0.846 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Bal Pharma Limited 相関 - 通貨/商品
Bal Pharma Limited 財務諸表
Annual | 2022 |
収益: | INR3.04B |
総利益: | INR1.31B (43.21 %) |
EPS: | INR1.640 |
FY | 2022 |
収益: | INR3.04B |
総利益: | INR1.31B (43.21 %) |
EPS: | INR1.640 |
FY | 2022 |
収益: | INR2.81B |
総利益: | INR1.11B (39.64 %) |
EPS: | INR3.79 |
FY | 2021 |
収益: | INR2.51B |
総利益: | INR993.03M (39.64 %) |
EPS: | INR3.34 |
Financial Reports:
No articles found.
Bal Pharma Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR1.000 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR1.000 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.750 | 2006-09-07 |
Last Dividend | INR1.000 | 2023-09-18 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 14 | -- |
Total Paid Out | INR13.00 | -- |
Avg. Dividend % Per Year | 0.69% | -- |
Score | 1.51 | -- |
Div. Sustainability Score | 1.444 | |
Div.Growth Potential Score | 2.53 | |
Div. Directional Score | 1.985 | -- |
Year | Amount | Yield |
---|---|---|
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR1.000 | 1.18% |
2019 | INR1.000 | 1.27% |
2020 | INR0 | 0.00% |
2021 | INR1.000 | 1.78% |
2022 | INR1.000 | 0.79% |
2023 | INR1.000 | 1.09% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
REVATHI.NS | No Dividend Player | 2023-09-27 | Sporadic | 19 | 0.12% | |
KTKBANK.NS | Dividend Junior | 2023-08-22 | Annually | 24 | 2.55% | |
FINPIPE.NS | Dividend Junior | 2023-08-21 | Annually | 23 | 0.73% | |
ANURAS.NS | Dividend Junior | 2023-05-15 | Semi-Annually | 4 | 0.14% | |
TATAMOTORS.NS | Dividend Junior | 2023-07-28 | Sporadic | 29 | 0.14% | |
NOCIL.NS | Dividend Junior | 2023-07-24 | Annually | 19 | 1.11% | |
INDOBORAX.NS | Dividend Junior | 2023-08-11 | Annually | 3 | 0.35% | |
COALINDIA.NS | Dividend King | 2023-08-18 | Semi-Annually | 14 | 6.39% | |
SATIA.NS | Dividend Junior | 2023-09-22 | Annually | 6 | 0.35% | |
MAHINDCIE.NS | Dividend Junior | 2023-06-02 | Annually | 3 | 0.66% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0142 | 1.500 | 9.72 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.0729 | 1.500 | -0.301 | -0.451 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 1.455 | 1.000 | -0.572 | -0.572 | [3 - 30] |
operatingCashFlowPerShareTTM | 12.66 | 2.00 | 5.78 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 12.66 | 2.00 | 3.67 | 7.34 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.440 | 1.000 | 6.00 | 6.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0666 | 1.000 | -0.667 | -0.667 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.444 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 33.48 | 1.000 | 6.72 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0729 | 2.50 | -0.193 | -0.451 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 12.66 | 2.00 | 5.78 | 7.34 | [0 - 30] |
dividendYielPercentageTTM | 1.019 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 12.66 | 2.00 | 5.78 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.590 | 1.500 | -7.27 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0612 | 1.000 | -0.970 | 0 | [0.1 - 0.5] |
Total Score | 2.53 |
Bal Pharma Limited
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。